PMID- 37509419
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230731
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 7
DP  - 2023 Jun 21
TI  - K(Ca)2 and K(Ca)3.1 Channels in the Airways: A New Therapeutic Target.
LID - 10.3390/biomedicines11071780 [doi]
LID - 1780
AB  - K(+) channels are involved in many critical functions in lung physiology. 
      Recently, the family of Ca(2+)-activated K(+) channels (K(Ca)) has received more 
      attention, and a massive amount of effort has been devoted to developing 
      selective medications targeting these channels. Within the family of K(Ca) 
      channels, three small-conductance Ca(2+)-activated K(+) (K(Ca)2) channel 
      subtypes, together with the intermediate-conductance K(Ca)3.1 channel, are 
      voltage-independent K(+) channels, and they mediate Ca(2+)-induced membrane 
      hyperpolarization. Many K(Ca)2 channel members are involved in crucial roles in 
      physiological and pathological systems throughout the body. In this article, 
      different subtypes of K(Ca)2 and K(Ca)3.1 channels and their functions in 
      respiratory diseases are discussed. Additionally, the pharmacology of the K(Ca)2 
      and K(Ca)3.1 channels and the link between these channels and respiratory ciliary 
      regulations will be explained in more detail. In the future, specific modulators 
      for small or intermediate Ca(2+)-activated K(+) channels may offer a unique 
      therapeutic opportunity to treat muco-obstructive lung diseases.
FAU - Orfali, Razan
AU  - Orfali R
AUID- ORCID: 0000-0002-0584-4013
AD  - Department of Biomedical and Pharmaceutical Sciences, Chapman University School 
      of Pharmacy, Irvine, CA 92618, USA.
AD  - Biomedical Research Administration, Research Centre, King Fahad Medical City, 
      Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
FAU - AlFaiz, Ali
AU  - AlFaiz A
AD  - Biomedical Research Administration, Research Centre, King Fahad Medical City, 
      Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
FAU - Rahman, Mohammad Asikur
AU  - Rahman MA
AD  - Department of Biomedical and Pharmaceutical Sciences, Chapman University School 
      of Pharmacy, Irvine, CA 92618, USA.
FAU - Lau, Liz
AU  - Lau L
AD  - Department of Biomedical and Pharmaceutical Sciences, Chapman University School 
      of Pharmacy, Irvine, CA 92618, USA.
FAU - Nam, Young-Woo
AU  - Nam YW
AD  - Department of Biomedical and Pharmaceutical Sciences, Chapman University School 
      of Pharmacy, Irvine, CA 92618, USA.
FAU - Zhang, Miao
AU  - Zhang M
AUID- ORCID: 0000-0002-3099-155X
AD  - Department of Biomedical and Pharmaceutical Sciences, Chapman University School 
      of Pharmacy, Irvine, CA 92618, USA.
LA  - eng
GR  - 4R33NS10118203/GF/NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20230621
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10376499
OTO - NOTNLM
OT  - KCa2 channels
OT  - anosmia
OT  - chronic obstructive pulmonary diseases
OT  - cystic fibrosis
OT  - lungs
OT  - motile cilia
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:47
MHDA- 2023/07/29 11:48
PMCR- 2023/06/21
CRDT- 2023/07/29 01:12
PHST- 2023/05/22 00:00 [received]
PHST- 2023/06/08 00:00 [revised]
PHST- 2023/06/13 00:00 [accepted]
PHST- 2023/07/29 11:48 [medline]
PHST- 2023/07/29 11:47 [pubmed]
PHST- 2023/07/29 01:12 [entrez]
PHST- 2023/06/21 00:00 [pmc-release]
AID - biomedicines11071780 [pii]
AID - biomedicines-11-01780 [pii]
AID - 10.3390/biomedicines11071780 [doi]
PST - epublish
SO  - Biomedicines. 2023 Jun 21;11(7):1780. doi: 10.3390/biomedicines11071780.